Assetmark Inc. Buys 33,902 Shares of Takeda Pharmaceutical Co. $TAK

Assetmark Inc. grew its stake in Takeda Pharmaceutical Co. (NYSE:TAK) by 27.7% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 156,120 shares of the company’s stock after purchasing an additional 33,902 shares during the period. Assetmark Inc.’s holdings in Takeda Pharmaceutical were worth $2,434,000 as of its most recent SEC filing.

Other institutional investors and hedge funds also recently made changes to their positions in the company. True Wealth Design LLC grew its holdings in shares of Takeda Pharmaceutical by 1,262.3% during the 3rd quarter. True Wealth Design LLC now owns 2,711 shares of the company’s stock worth $40,000 after purchasing an additional 2,512 shares in the last quarter. Northwestern Mutual Wealth Management Co. raised its stake in shares of Takeda Pharmaceutical by 56.3% in the second quarter. Northwestern Mutual Wealth Management Co. now owns 3,586 shares of the company’s stock valued at $55,000 after purchasing an additional 1,292 shares in the last quarter. Advisory Services Network LLC bought a new position in Takeda Pharmaceutical in the third quarter worth $74,000. Farther Finance Advisors LLC lifted its position in Takeda Pharmaceutical by 24.5% in the third quarter. Farther Finance Advisors LLC now owns 7,001 shares of the company’s stock worth $102,000 after purchasing an additional 1,378 shares during the period. Finally, Global Trust Asset Management LLC acquired a new stake in Takeda Pharmaceutical during the third quarter worth $110,000. Institutional investors own 9.17% of the company’s stock.

Wall Street Analyst Weigh In

A number of research firms recently weighed in on TAK. Sanford C. Bernstein raised shares of Takeda Pharmaceutical from a “market perform” rating to an “outperform” rating in a research note on Wednesday, April 8th. Weiss Ratings restated a “hold (c-)” rating on shares of Takeda Pharmaceutical in a research note on Monday, December 29th. Zacks Research raised Takeda Pharmaceutical from a “strong sell” rating to a “hold” rating in a report on Tuesday, March 3rd. Wall Street Zen upgraded Takeda Pharmaceutical from a “buy” rating to a “strong-buy” rating in a research note on Saturday, April 11th. Finally, Morgan Stanley started coverage on Takeda Pharmaceutical in a report on Tuesday, January 13th. They issued an “overweight” rating for the company. Two analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company’s stock. Based on data from MarketBeat.com, Takeda Pharmaceutical presently has a consensus rating of “Moderate Buy”.

Takeda Pharmaceutical Stock Down 1.4%

Shares of NYSE:TAK opened at $17.57 on Tuesday. The company has a quick ratio of 0.65, a current ratio of 1.19 and a debt-to-equity ratio of 0.56. The firm has a market cap of $55.90 billion, a P/E ratio of 73.19 and a beta of -0.01. Takeda Pharmaceutical Co. has a 12 month low of $12.99 and a 12 month high of $18.90. The company’s 50-day moving average price is $18.23 and its two-hundred day moving average price is $16.13.

Takeda Pharmaceutical (NYSE:TAK) last released its earnings results on Friday, January 30th. The company reported $0.48 earnings per share for the quarter, missing analysts’ consensus estimates of $0.55 by ($0.07). The firm had revenue of $7.60 billion for the quarter, compared to the consensus estimate of $7.81 billion. Takeda Pharmaceutical had a return on equity of 10.60% and a net margin of 2.58%.Takeda Pharmaceutical has set its FY 2025 guidance at 3.160-3.160 EPS. As a group, research analysts forecast that Takeda Pharmaceutical Co. will post 1.58 EPS for the current fiscal year.

About Takeda Pharmaceutical

Takeda Pharmaceutical Company Limited (NYSE: TAK) is a Tokyo-based, multinational biopharmaceutical company with roots dating back to 1781. The company researches, develops, manufactures and commercializes pharmaceutical and biopharmaceutical products for patients worldwide. Takeda is publicly listed and operates as a fully integrated R&D-driven healthcare company focused on delivering specialty medicines and therapies across a range of therapeutic areas.

Takeda’s main business activities encompass discovery and development of prescription medicines, clinical development and regulatory affairs, manufacturing of small molecules and biologics, and global commercial operations.